- Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99.
- Sanofi said the new price would be effective from July 1.
- The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure.
- Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “which limits out-of-pocket expenses for a majority of people between $0 and $10.” But the company also confirmed that some diabetics taking Sanofi’s insulins would see savings with the House bill.
- Reuters said that Sanofi, Eli Lilly And Co (NYSE:LLY), and Novo Nordisk A/S (NYSE:NVO) make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.
- Price Action: SNY shares are up 1.36% at $52.85 during the market session on the last check Wednesday.
- Photo by Towfiqu Barbhuiya via Unsplash
